期刊文献+

纳米板转导HPV18 E7siRNA对宫颈癌细胞增殖的抑制作用 被引量:1

Nanopatch-delivered HPV18 E7 siRNA inhibits proliferation of skin cells in cervical cancer transgenic mice
下载PDF
导出
摘要 目的通过纳米板转导HPV18 E7 siRNA进入HPV18 E7宫颈癌转基因鼠皮肤组织,探讨纳米板转导siRNA的效率及转导的siRNA对宫颈癌细胞增殖的抑制作用。方法纳米板转导FITC标记的寡聚DNA(代替siRNA)进入小鼠皮肤,观察荧光变化,判断DNA是否被转导进入皮肤细胞中;纳米板转导DiI标记脂质体与siRNA复合物进入小鼠皮肤,测定转导前后和残留在皮肤上的荧光强度,计算纳米板转导siRNA进入组织细胞的效率;纳米板转导E7 siRNA和脂质体的复合物于转基因鼠皮肤中后,BrDU免疫组化检测siE7对宫颈癌细胞增殖的抑制作用。结果纳米板转导寡聚DNA后绿色荧光逐渐分散变多,表明DNA已逐渐进入小鼠皮肤细胞中。纳米板转导DiI标记脂质体与siRNA进入小鼠皮肤后,通过荧光强度计算得出转染率为50.23%。纳米板转导E7 siRNA进入HPV18 E7宫颈癌转基因鼠皮肤后,能有效抑制宫颈癌细胞增殖。结论纳米板能高效的转导siRNA进入组织细胞,并且转导进入细胞的siE7能有效抑制宫颈癌细胞增殖。 Objective To explore the efficiency of siRNA delivery by using nanopatch and the inhibi- tory effect of HPV18 E7 siRNA (siE7) on the proliferation of skin cells in cervical cancer transgenic mice. Methods The oligonucleotide tagged with FITC as a substitute of siRNA was delivered into mouse skin by nanopatch, and the green fluorescence was observed to analyze whether the nanopatch can deliver siRNA into the cells of mouse skin. Nanopatch was used to deliver the complexes of siE7 and liposomes marked with DiI into mouse skin. The fluorescence intensity of DiI before and after transfection and that remained on the surface of mouse skin after transfection were determined. The efficiency of siE7 delivery by nanopatch was calculated, and BrdU immunohistochemistry was applied to detect the proliferation of skin cells transfected with siE7 in cervical cancer transgenic mice. Results The green fluorescence detected by confocal laser scanning microscopy (CLSM) after transfection by nanopateh increased and scattered, suggesting the oligonucleotide was delivered into skin cells. The transfection efficiency of using nanopatch to deliver siRNA was 50.23 %. The proliferation of transgenic mouse skin cells transfected with siE7 by nanopatch was inhibited. Conclusion Nanopatch can effectively deliver siRNA into mouse skin ceils, and siE7 delivered by nanopatch can inhibit the proliferation of skin cells of cervical cancer transgenic mice.
出处 《第三军医大学学报》 CAS CSCD 北大核心 2013年第12期1242-1246,共5页 Journal of Third Military Medical University
基金 重庆市卫生局医学科研计划(2010-2-162) 重庆市教委科学技术研究项目(KJ110310) 重庆市自然科学基金(CSTC2009BB5071) 浙江省教育厅科研项目(Y201017552)~~
关键词 宫颈癌 纳米板 RNA干扰 人乳头状瘤病毒 cervical cancer nanopatch RNA interference human papillomavirus
  • 相关文献

参考文献16

  • 1Yoshinouchi M, Yamada T, Kizaki M, et al. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA[ J]. Mol Ther, 2003, 8 (5) : 762 - 768.
  • 2Chang J T, Kuo T F, Chen Y J, et al. Highly potent and specific siR- NAs against E6 or E7 genes of HPV16- or HPV18-infected cervical cancers [ J ]. Cancer Gene Ther, 2010, 17 (12) : 827 - 836.
  • 3GuW, Putral L, Hengst K, et al. Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenes [ J ]. Canc- er Gene Ther. 2006. 13(11 : 1023 -1032.
  • 4Kendall M A, Chong Y F, Cock A. The mechanical properties of the skin epidermis in relation to targeted gene and drug delivery[ J]. Bio- materials, 2007, 28 (33): 4968-4977.
  • 5Kendall M. Engineering of needle-free physical methods to target epidermal cells for DNA vaccination[J]. Vaccine, 2006, 24(21 ): 4651 -4656.
  • 6Chen X, Prow T W, Crichton M L, et al. Dry-coated microprojectionarray patches for targeted delivery of immunotherapeutics to the skin [J]. J Control Release, 2009, 139(3) : 212 -220.
  • 7Roden R B, Gravitt P, Wu T C. Towards global prevention of human papillomavirus-induced cancer[ J ]. Eur J Immunol, 2008, 38 (2) : 323 - 326.
  • 8Andersson S, Rylander E, Larsson B, et al. The role of human papil- lomavirus in cervical adenocarcinoma carcinogenesis[ J]. Eur J Canc- er, 2001,37(2) : 246 -250.
  • 9Munoz N, Bosch F X, de-Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer[J]. N Engl J Med, 2003, 348(6) : 518 -527.
  • 10Brantl S. Antisense-RNA regulation and RNA interference [ J ]. Bio- chim Biophys Acta, 2002, 1575 (1/3) : 15 - 25.

二级参考文献12

  • 1安立峰,董震.RNA干扰——肿瘤研究的新工具[J].中华肿瘤杂志,2005,27(7):385-388. 被引量:38
  • 2Shinkaruk S, Bayle M, lain G, et al. Vascular endothelial cell growth factor (VEGF) , an emerging target for cancer chemotherapy[J]. Curr Med Chem Anticancer Agents, 2003, 3 (2) : 95 - 117.
  • 3Masood R, Cai J, Zheng T, et al. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors[J]. Blood, 2001,98(6) : 1904-1913.
  • 4de Jong JS, van Diest PJ, van der Valk P, et al. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer, Ⅱ: Correlations with proliferation and Angiogenesis [ J ]. J Pathol, 1998, 184( 1 ) : 53 -57.
  • 5Kasukabe T, Okabe-Kado J, Kato N, et al. Effects of combined treatment with rapamyein and eotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts [ J ]. Breast Cancer Res, 2005, 7(6): R1097- 1110.
  • 6Ferrara N. VEGF: an update on biological and therapeutic aspects [J]. Curt Opin Biotechnol, 2000, 11(6) : 617 -624.
  • 7Lacal PM, Ruffini F, Pagani E, et al. An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells[ J]. Int J Oncol, 2005, 27(6) : 1625 - 1632.
  • 8Dorsett Y, Tuschl T. siRNAs: applications in functional genomics and potential as therapeutics [ J ]. Nat Rev Drug Discov, 2004, 3 (4) : 318 -329.
  • 9Layzer JM, McCaffrey AP, Tanner AK, et al. In vivo activity of nuclease-resistant siRNAs[J]. RNA, 2004, 10(5): 766-771.
  • 10Schiffelers RM, Ansari A, Xu J, et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle[J]. Nucleic Acids Res, 2004, 32(19) : 149.

共引文献12

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部